The core and extended Adjuvant teams are anchored by experienced venture capital and private equity investors, global public health leaders, disease-specific technical experts, and pharmaceutical industry veterans. Our deep ties to the global health community and our long-standing relationships with major funders and decision-makers are essential components of our investment sourcing and execution process.
Founder and Managing Partner / New York
Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director. He is still active on a number of GHIF projects, including board seats at several innovative life sciences companies such as Univercells, Themis (acquired by Merck in 2020), and EuBiologics (listed on KOSDAQ in 2017: 206650.KQ). Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018, and as a founding director at Moxidectin for Onchocerciasis Ltd., which ultimately led to the “unprecedented approval” of the first new treatment for river blindness by the US FDA in 20 years.
At Adjuvant, Glenn oversees the firm’s investments in X-Vax (board observer), InDevR (board member), and Codagenix (board member). He is also actively engaged with the Research Investment for Global Health Technology Fund (RIGHT Fund) as a board member and a champion of leveraging the strengths of South Korea’s life sciences industry to bring new public health innovations to market. True to his conviction in the power of capital markets and impact investing to drive improvements in livelihoods around the world, he recently added a board seat at WaterEquity to his commitments.
Prior to his GHIF/Adjuvant roles, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, museums, and other mission-driven organizations. He earned an AB in public policy from the Princeton School of Public and International Affairs.
Managing Partner / San Francisco
Jenny has worked in finance for more than 16 years, beginning as an investment banker advising corporate clients in mergers and acquisitions, and debt and equity financings at Goldman Sachs’ Hong Kong, New York, and San Francisco offices. She has always been passionate about improving the health and lives of those living in low- and middle-income countries and spent time working and living in Kenya and China. In Kenya, Jenny spent almost a year as a volunteer consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.
In 2012, the Bill & Melinda Gates Foundation (BMGF) was expanding its strategic investment efforts from a pilot program to a larger scale fund. As part of a small but growing team, Jenny pushed the envelope on how private foundations could achieve charitable objectives by using philanthropic capital and program-related investments to complete equity, debt, structured finance, and guarantee investments in companies and investment funds. Jenny led transactions across the foundation’s focus areas in global health, agriculture, nutrition, and education. She represented BMGF’s interests on numerous boards including Kymab (UK), Acrobatiq (US), Ustar Technologies (China), and Owl Ventures (USA). She also serves on the Investment Advisory Committee at the Reproductive Health Investors’ Alliance (US).
Jenny graduated magna cum laude from Harvard University with an AB in History of Science.
Partner / San Diego
In addition to her role at Adjuvant, Kim is also currently a Partner at Domain Associates where she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine.
Present board memberships include Aspen Neuroscience, Epic Sciences, Evofem Biosciences, Obalon Therapeutics, Omniome, Seraphina, Sera Prognostics, Singular Genomics, and Truvian Sciences. She also helped to create and was formerly a board member of Syndax Pharmaceuticals and Tragara Pharmaceuticals. Kim was involved with Ariosa Diagnostics until the company was sold to Roche in January 2015, Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to Sanofi in April 2009.
Kim is also a Kauffman Fellow alum. Prior to Domain, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Kim serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is a former advisor to the Bill & Melinda Gates Foundation.
Principal / New York
Kabeer helped found Adjuvant Capital after three years with the Global Health Investment Fund (GHIF). While at GHIF he was responsible for sourcing and analyzing new opportunities, including co-leading the fund’s investments in Univercells, Themis, Access Bio, and Atomo Diagnostics. He has supported projects across the entire GHIF portfolio and continues to be involved as a board observer to several active partnerships.
Prior to GHIF, Kabeer was an investment professional at Metalmark Capital, a private equity fund in New York, where he focused primarily on medical device investments. Kabeer also spent time at Greenhill & Co., a boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medical technology sectors. He graduated with honors from the Stern School of Business at New York University with a BS in Finance & Economics.
Principal / New York
Charlie helped found Adjuvant Capital while at the Global Health Investment Fund (GHIF) where he focused on investments in medical device companies, including the fund’s investments in IanTech (acquired by Zeiss) and Alydia Health.
Before joining GHIF, Charlie was with Artemis Capital Partners, where he made private equity investments in industrial technology companies with a focus on the scientific instrumentation and advanced materials sectors. Previously, he lived in Haiti and worked at the country’s largest microfinance bank, Sevis Finansye Fonkoze, where he led financial and operational analysis efforts. Charlie remains active in Haiti and serves on the boards of Sevis Finansye Fonkoze and Fonkoze USA. He is a graduate of the Virginia Polytechnic Institute.
Principal / New York
Michael joined the Adjuvant investment team from the Bill & Melinda Gates Foundation (BMGF) where he worked with its Global Health Division and Strategic Investment Fund to structure investments into biotech companies, leading academic centers, and other non-profit organizations that have the goal of stimulating technological innovation in global health. Michael has experience investing in the development of drugs, vaccines, diagnostics, and health data solutions across a range of high-burden and neglected disease areas.
Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University.
Lilly deSouza Burr
Associate / New York
Lilly deSouza Burr
Lilly joined the Adjuvant investment team from Citi, where she was a senior associate in Citi’s healthcare investment banking group, advising clients across the biotech, pharma, medtech and services sectors on strategic and operational planning, M&A transactions and equity and debt financings. Prior to Citi, Lilly practiced law in the M&A group at Davis Polk & Wardwell, LLP. Lilly also spent time before law school at the Neurosciences Clinic at the Ottawa Hospital, where she managed a clinical neurosurgery practice and focused on spinal cord injury research.
She holds a JD from Georgetown University Law Center and a BS from the University of Ottawa.
Finance Director / New York
Evelyn is a senior financial professional and provides outsourced operational, regulatory, and audit and tax oversight services to Adjuvant. She has extensive experience in investment analysis and valuation, fundraising, SEC and other financial reporting, accounting, audit and tax.
Evelyn received a BS in Accounting from Binghamton University and an MBA from the Fordham Gabelli School of Business. She is a Certified Public Accountant in New York State.
Gerard is an Operating Partner with Adjuvant Capital and has 25 years of experience in the vaccine industry, global health partnerships and consulting. As an Operating Partner with Adjuvant Capital, Gerard supports the Fund’s assessment of global health innovations, and support portfolio companies as they develop and deliver new products to improve public health outcomes in low- and middle-income countries.
Gerard has worked vaccine development and delivery for almost two decades, including leadership of the new vaccine planning function at Merck. He spent more than three years working at the Bill & Melinda Gates Foundation (BMGF) where he supported the HIV, TB, and malaria program teams, and worked closely with a range of partners including multinational corporations, emerging market manufacturers, the WHO, UNICEF, Gavi, and others to support delivery of new vaccines and polio eradication.
During his tenure at BMGF, Gerard negotiated several partnerships to drive access to new vaccines. He was responsible for assessments of new technologies for the inactivated polio vaccine (IPV) as well as partner/supplier assessments, providing leadership for technical, financial and legal diligence efforts for multiple manufacturers.
Gerard has served as a Senior Advisor to the Global Health Investment Fund since its inception in 2012, and provided diligence and operational support for four of the Fund’s investments.
Gerard has an MA (Engineering) and a M. Eng. (Manuf. Engineering) degree from Cambridge University, in addition to an MBA (Marketing & International Business) from the University of Michigan
Venture Partner / New York
Curt has been investing in healthcare companies for over 16 years. He has served as a board member or observer for many successful companies, including KAI Pharmaceuticals (sold to Amgen), Sirion Therapeutics (sold to B&L and Alcon), Impulse Monitoring (sold to NuVasive), TransMolecular (sold to Morphotek), Estech (sold to Atricure), Coherex (sold to J&J), Exagen Diagnostics, SafeOp and others. Curt was previously a managing director at Tullis Health Investors and a vice president at Investor Growth Capital. He holds a BS in economics from Brigham Young University, and both MD and MBA degrees from Columbia University.
Mark Sullivan has 11 years executive management, advisory board, and board of directors experience in biotechnology and 28 years of experience in clinical development within the biotechnology, large pharmaceutical, contract services, and academic sectors. His drug development experience encompasses project leadership of five biopharmaceutical products, with his most recent program securing FDA approval in June 2018, and extensive practical experience implementing clinical studies across all stages of development.
Mr. Sullivan led the team responsible for one of GHIF’s more rewarding social and financial investments: seeing the moxidectin program through the final stages of development and securing regulatory approval for the drug as the first new treatment for onchocerciasis registered with the FDA in more than 20 years.
Senior Advisor / San Francisco
Dr. Sophie Allauzen has 20 years of international experience in R&D, business development, and portfolio management in various diagnostic industries managing the full life-cycle of novel diagnostic products (R&D, planning, commercialization, and registration) in developed and developing worlds. Sophie’s experience includes the Bill & Melinda Gates Foundation where she oversaw malaria and a portfolio of neglected diseases diagnostic programs, Novartis Diagnostics as Head of Blood Testing running the NAT/Immunohematology product portfolio, and Bio-Rad managing the R&D department for the development of bead multi-array immuno-assays. Prior moving to the U.S., Sophie spent five years at Sanofi Diagnostics Pasteur in France, in R&D working on the development of various tests for infectious diseases.
Sophie holds a PhD in biochemistry/immunology from Montpellier University, France, directed toward auto-immune disease mechanisms, and completed her postdoc fellow position in allergy at University of Minnesota.
She is currently an independent consultant based in San Francisco, CA.
Senior Advisor / Boston
Christian W. Mandl, Ph.D., M.D. is a Senior Advisor to Adjuvant Capital, and he provides consulting services to industry partners and non-profit organizations around the world for vaccine and viral vector programs. Previously he was the Senior Vice President of Research for VIR Biotechnology (San Francisco, CA). Until 2015, he was Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying RNA technology (SAM®), which he initiated inspired by his previous academic research.
Prior to joining Novartis in 2008, Christian was Professor and Assistant Head of the Clinical Institute of Virology at Medical University of Vienna. His academic research focused on molecular mechanisms of RNA viruses, their interactions with host organisms targeting novel medical applications, enabling new antiviral strategies and applications in vaccine development or viral gene vectors. He is a world-renowned expert in the molecular biology of flaviviruses and RNA vaccines. He has authored more than 100 scientific publications, and is an inventor on patents related to a marketed tick-borne encephalitis (flavivirus) vaccine, the SAM technology, and other antiviral approaches. Christian holds a PhD and MD from University of Vienna, and a Master of Science (Biochemistry) from Pennsylvania State University. He earned his postdoctoral lecturer qualification (Habilitation) in Molecular Virology and was certified as a Medical Specialist in Virology by the Austrian Medical Association.
His engagement with the health care industry and public health organizations includes roles as a Co-founder and Chair, Scientific Advisory Board for Tiba Biotech (Cambridge, MA), Chair, Scientific Advisory Board for Themis Biotech (Vienna, Austria), and Chair, Scientific Advisory Group for the International Vaccine Institute (Seoul, Korea).
Jim Robinson is an accomplished biologics manufacturing expert with decades of industry experience across a wide range of institutions. From 2010 to 2015, he served as Vice President, Global Technical Operations, Vaccines, Biological and Sterile Products for Merck & Co., Inc., where he oversaw improvements to the company’s manufacturing operations in order to increase supply performance and capacity realization for the vaccine, biologics and sterile products franchises (combined $11 billion in annual sales). From 2007 to 2010, he was Vice President, Technical and Quality Operations at Novavax, Inc., managing a 40-person biotechnology team focused on recombinant virus-like particle vaccines. The prior 20 years were spent in various positions with Sanofi Pasteur, including, from 1998 to 2006, as Vice President, Industrial Operations. Mr. Robinson has been granted various international patents, serves on a number of Scientific Advisory Boards and Councils, such as his Vice Chair role on CEPI’s Scientific Advisory Committee, and is the author of an array of publications covering vaccines and biologics manufacturing. He holds Master’s and Bachelor’s degrees in Chemical Engineering from Lehigh University.
Senior Advisor / DC
Peter A. Patriarca, M.D., is the Principal of Immuno-Vax, LLC, and a senior affiliate consultant with Biologics Consulting Group, Inc. (Alexandria, Virginia). He has provided technical and regulatory consulting services for all phases of vaccine and other biological products development for the past 14 years for over 500 projects. Prior to consulting, Dr. Patriarca was Corporate Head and Vice President, Worldwide Regulatory Affairs and Pharmacovigilance at MedImmune, Inc. (2001-2005) and also served as Medical Officer in the U.S. Public Health Service at the Centers for Disease Control and Prevention (1980-1992) and the US Food and Drug Administration (1993-2001). At FDA, Dr. Patriarca served, among other positions, as Director of the Division of Viral Products in the Office of Vaccines Research and Review (OVRR), CBER. In that capacity, he oversaw research and review activities of more than 100 scientific staff in eight laboratories, and was intimately involved with regulatory decisions and policy affecting vaccine development and licensure. While at CDC, Dr. Patriarca was assigned to the National Immunization Program, where, among other positions, he served as the Chief Medical Epidemiologist in the Influenza Division and the first head of CDC’s program in support of the Global Poliomyelitis Eradication Initiative. He has authored more than 100 peer-review publications and has served on multiple scientific advisory bodies for CDC, WHO, the Bill and Melinda Gates Foundation, the American Academy of Pediatrics, the National Academy of Sciences, and numerous pharmaceutical companies.